PMC:3724972 / 20346-21231 JSONTXT

{"project":"2_test","denotations":[{"id":"23673515-18957506-63233650","span":{"begin":83,"end":85},"obj":"18957506"},{"id":"23673515-22397653-63233651","span":{"begin":209,"end":211},"obj":"22397653"},{"id":"23673515-20497937-63233652","span":{"begin":442,"end":444},"obj":"20497937"},{"id":"23673515-15126577-63233653","span":{"begin":580,"end":582},"obj":"15126577"},{"id":"23673515-18957500-63233654","span":{"begin":584,"end":586},"obj":"18957500"},{"id":"23673515-22851491-63233655","span":{"begin":779,"end":781},"obj":"22851491"}],"text":"Compound Trial Patients (N) Treatment duration Outcome\nPasireotide Boscaro et al. [40] 29 15 days 5/29 patients (17 %) achieved UFC ≤ ULN; 22/29 patients (76 %) experienced reduction in mean UFC\nColao et al. [43] 162 12 months 33/162 patients (20 %) achieved UFC ≤ ULN within 6 months without increase from randomized dose; the majority of patients experienced reduction in UFC at month 6, sustained through month 12\nCabergoline Lila et al. [52] 18 5 months 5 patients (28 %) achieved MNSC \u003c5 μg/dL or low-dose dexamethasone-suppressed serum cortisol \u003c1.8 μg/dL\nPivonello et al. [48, 53] 20 3–24 months After 3 months, 15 patients (75 %) achieved UFC ≤ ULN or ≥25 % reduction from baseline; 8 patients (40 %) maintained UFC ≤ ULN at 24 months\nRetinoic acid Pecori Girald et al. [59] 7 6–12 months 3/7 patients (43 %) achieved UFC ≤ ULN; 5/7 patients (71 %) experienced reduction in UFC"}